7.14

4.39% 0.30

Day One Biopharmaceuticals Inc (DAWN)

Overview News Price History Option Chain Financials Discussions Forecast

Day One Biopharmaceuticals Inc stock is traded at $7.14, with a volume of 1.94M. It is up +4.39% in the last 24 hours and down -13.24% over the past month. Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, and kinase inhibitor.

Previous Close:

$6.84

Open:

$6.75

24h Volume:

1.94M

Relative Volume:

1.70

Market Cap:

$731.77M

Revenue:

Net Income/Loss:

$-167.48M

P/E Ratio:

-3.6615

EPS:

-1.95

Net Cash Flow:

$-197.47M

1W Performance:

-1.11%

1M Performance:

-13.24%

6M Performance:

-52.18%

1Y Performance:

-52.27%

1-Day Range:

$6.73

$7.55

1-Week Range:

$6.63

$7.55

52-Week Range:

$6.41

$18.07

Day One Biopharmaceuticals Inc Stock (DAWN) Company Profile

Name

Day One Biopharmaceuticals Inc

Sector

Healthcare (1155)

Industry

Biotechnology (677)

Phone

650 484-0899

Address

2000 SIERRA POINT PARKWAY, SUITE 501, BRISBANE

Employee

181

Twitter

Next Earnings Date

Latest SEC Filings

DAWN's Discussions on Twitter

Compare DAWN with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
DAWN Day One Biopharmaceuticals Inc	7.14	731.77M	0	-167.48M	-197.47M	-1.95
VRTX Vertex Pharmaceuticals Inc	477.52	127.47B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	561.49	62.43B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	595.70	37.03B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	232.75	31.06B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	229.22	26.16B	3.81B	-644.79M	-669.77M	-6.24

Day One Biopharmaceuticals Inc Stock (DAWN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-09-24	Reiterated	Needham	Buy
Aug-01-24	Upgrade	BofA Securities	Underperform → Buy
Apr-24-24	Reiterated	Needham	Buy
Apr-25-23	Downgrade	BofA Securities	Buy → Underperform
Feb-08-23	Initiated	CapitalOne	Overweight
Feb-03-23	Initiated	Oppenheimer	Perform
Dec-15-22	Initiated	H.C. Wainwright	Buy
Dec-14-22	Initiated	Needham	Buy
Dec-05-22	Initiated	Goldman	Buy
Dec-01-22	Initiated	BofA Securities	Buy

View All

Day One Biopharmaceuticals Inc Stock (DAWN) Latest News

Apr 21, 2025

What is Day One Biopharmaceuticals Inc (DAWN) Stock Return on Shareholders’ Capital? - Sete News

Apr 21, 2025

Finance Watch: No Big Post-ASCO Follow-On Frenzy, But Biotech Had A Good Week - insights.citeline.com

Apr 21, 2025

Apr 20, 2025

Geode Capital Management LLC Has $18.54 Million Holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - Defense World

Apr 20, 2025

Apr 17, 2025

BofA Adjusts Price Target on Day One Biopharmaceuticals to $21 From $24, Keeps Buy Rating - marketscreener.com

Apr 17, 2025

Apr 11, 2025

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Shares Sold by Corebridge Financial Inc. - Defense World

Apr 11, 2025

Vanguard Group Inc. Lowers Stock Holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - Defense World

Apr 11, 2025

Apr 10, 2025

Day One Biopharmaceuticals Pullback Is A Potential Buying Opportunity - Seeking Alpha

Apr 10, 2025